What question did this study set out to answer?

To engineer and evaluate anti-ED-B fibronectin scFv-modified liposomes for targeted biodistribution and cytotoxic drug delivery to F9 teratocarcinoma tumors.

June 25, 2002British Journal of CancerOpen Access

Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes

View Full Paper

Ask AI

Bookmark

To engineer and evaluate anti-ED-B fibronectin scFv-modified liposomes for targeted biodistribution and cytotoxic drug delivery to F9 teratocarcinoma tumors.
Functionalized small unilamellar liposomes with anti-ED-B scFv fragments via maleimide-PEG phospholipids and evaluated binding in vitro on Caco-2 cells.
Assessed in vivo tumor biodistribution of 114mIn-labeled scFv-modified liposomes versus unmodified controls in mice bearing subcutaneous F9 teratocarcinomas.
Administered five daily intravenous doses (30 mg/kg) of scFv-liposomes encapsulating a cytotoxic nucleotide analog to measure antitumor efficacy and histological changes.
Targeted liposomes showed 2- to 3-fold higher accumulation in tumors during the first 2 hours post-injection compared to unmodified liposomes, with both reaching 8-10% injected dose/g at 6-24 hours.
Cytotoxic targeted liposomes reduced tumor growth by 62% at day 5 and 90% at day 8 relative to control liposome-treated animals.
Histological analysis revealed extensive loss of F9 tumor cells accompanied by excessive fibronectin deposition throughout the tumor extracellular matrix.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates that anti-ED-B fibronectin scFv-modified liposomes suppress tumor growth by up to 90% in mice, highlighting a promising vascular-targeted drug delivery system.

Cite This Study

Marty et al. (2002) studied this question.

synapsesocial.com/papers/6a7048945d37378ac1dd5c3e https://doi.org/10.1038/sj.bjc.6600423

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates that anti-ED-B fibronectin scFv-modified liposomes suppress tumor growth by up to 90% in mice, highlighting a promising vascular-targeted drug delivery system.

Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes

Key Points

Discussion

Implication

Cite This Study

Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider